GLP1R and obesity due to melanocortin 4 receptor deficiency: Three GLP1-RAs-namely, liraglutide (Saxenda®), semaglutide (Wegovy®, Ozempic®), and tirzepatide (Zepbound®)-have secured approval from the U.S. Food and Drug Administration for obesity, while the remaining GLP-1RAs available in the market are solely indicated for glycemic control in T2DM.